Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.43 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.43 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.43 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.42 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598983 | 0.83 | GAA (0.57) | PTGS1PTGS2POLBTSHRHSD17B10 | |
| SCHEMBL9341624 | 0.83 | GAA (0.57) | PTGS1PTGS2POLBTSHRHSD17B10 | |
| SCHEMBL68932 | 0.83 | GAA (0.57) | PTGS1PTGS2POLBTSHRHSD17B10 | |
| SCHEMBL306418 | 0.81 | ALDH1A1 (0.59) | PTGS1PTGS2POLBCASP6KMT2A | |
| SCHEMBL2649250 | 0.81 | PTGS1 (0.51) | PTGS1PTGS2POLBTSHRHSD17B10 | |
| SCHEMBL1803937 | 0.81 | PTGS1 (0.66) | PTGS1PTGS2KMT2ACA2CA1 | |
| SCHEMBL1807429 | 0.81 | ALDH1A1 (0.59) | PTGS1PTGS2POLBCASP6KMT2A | |
| SCHEMBL126575 | 0.80 | LMNA (0.50) | PTGS1PTGS2HSD17B10LMNATDP1 | |
| SCHEMBL9492659 | 0.80 | SERPINE1 (0.59) | PTGS1PTGS2POLBAPOBEC3ACASP6 | |
| SCHEMBL11882785 | 0.79 | HSD17B3 (0.50) | PTGS1PTGS2POLBTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104678111-A | Method, reagent and kit for quantitatively detecting low-density lipoprotein cholesterol | ZHEJIANG KAICHENG BIOTECHNOLOGY CO LTD | 2015-06-03 | — | — | CN | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| EP-1966166-B1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1753732-B1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| EP-1966166-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | Sterix Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| EP-1753732-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118560-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | CYP19A1, CYP17A1, CYP21A2 | PTGS1 298/4885PTGS2 558/4885CA2 286/4885 |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | PTGS1 985/4885PTGS2 1326/4885CA2 502/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | PTGS1 2922/4885PTGS2 2885/4885CA2 1559/4885 |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | CYP19A1, CYP17A1, CYP21A2 | PTGS1 298/4885PTGS2 558/4885CA2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.